NetworkNewsBreaks – Avalon GloboCare Corp. (NASDAQ: AVCO) Files Patents, Expands Program Designed to Address Cytokine Storms
Avalon GloboCare (NASDAQ: AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, has expanded and filed two provisional patents with the U.S. Patent and Trademark Office. A result of Avalon’s AVA-Trap(TM) therapeutic program, the patents outline compositions and methods of developing a decoy cytokine receptor-based filter system to treat cytokine storms, a life-threatening condition that can cause multi-organ failure and death. “We are grateful for our strong scientific partnerships that enabled the rapid speed with which we are developing this novel clinical tool,” said Avon president and CEO Dr. David Jin in the press release. “This medical device holds enormous…







